DEFA14A: Neuronetics to Acquire Greenbrook TMS in Stock-Based Deal

Neuronetics will acquire Greenbrook TMS in a stock-for-stock transaction, aiming to create a leading player in the mental health treatment sector.

Summary

• Neuronetics, Inc. and Greenbrook TMS Inc. have entered into an arrangement agreement for Neuronetics to acquire all outstanding common shares of Greenbrook.
• Greenbrook shareholders will receive a fraction of a Neuronetics share, resulting in Greenbrook shareholders owning 43% and Neuronetics stockholders owning 57% of the combined company on a fully diluted basis.
• An aggregate of 25,304,971 shares of Neuronetics common stock will be issued to Greenbrook shareholders.
• The deal includes provisions for the cancellation or exchange of Greenbrook options, performance share units, restricted share units, and warrants.
• Upon completion, the Neuronetics board will consist of seven directors, with five appointed by Neuronetics and two by Madryn Asset Management LP.
• The arrangement is subject to customary conditions, including shareholder and court approvals, NASDAQ listing requirements, and debt conversions.
• The agreement includes termination rights and a termination fee of $1.9 million payable by either party under specified circumstances.
• Voting and support agreements have been entered into by key shareholders and directors of both companies to support the arrangement.
• Madryn Asset Management will have registration rights for the Neuronetics shares they receive.
• The transaction is expected to be exempt from registration under federal securities laws, relying on Section 3(a)(10) of the Securities Act.

Sentiment

Score: 7

Explanation: The document is primarily factual and descriptive, outlining the terms of the acquisition agreement. The sentiment is neutral to positive, reflecting the potential benefits of the merger, but tempered by the inherent risks and uncertainties associated with such transactions.

Positives

• The acquisition aims to create a stronger combined company in the mental health treatment sector.
• Key shareholders and directors of both companies support the arrangement through voting agreements.
• Madryn Asset Management gains registration rights, potentially enhancing liquidity for their investment.
• The transaction is structured to be exempt from federal securities registration, streamlining the process.

Negatives

• The deal is subject to customary conditions, including shareholder and court approvals, which could introduce uncertainty.
• Either party may be required to pay a $1.9 million termination fee under certain circumstances, representing a potential cost.
• Greenbrook performance share units and restricted share units will be cancelled for no consideration.

Risks

• The ability to meet expectations regarding the timing and completion of the Arrangement is a risk.
• The occurrence of any event, change or other circumstance that would give rise to the termination of the Arrangement Agreement is a risk.
• Greenbrook's and Neuronetics' respective stockholders may not approve the Arrangement Agreement and the Arrangement.
• The failure to satisfy each of the conditions to the consummation of the Arrangement is a risk.
• The disruption of management's attention from ongoing business operations due to the Arrangement is a risk.
• The effect of the announcement of the Arrangement on Greenbrook's and Neuronetics' relationships with their respective customers, as well as their respective operating results and business generally is a risk.
• The outcome of any legal proceedings related to the Arrangement is a risk.
• Retention of employees of Greenbrook following the announcement of the Arrangement is a risk.
• Greenbrook's and Neuronetics' stock price may decline significantly if the Arrangement is not completed.

Future Outlook

The document includes forward-looking statements regarding the proposed combination of Greenbrook and Neuronetics, potential benefits of the transaction and the timing thereof. These statements are subject to significant risks and uncertainties, and actual results could differ materially from those projected.

Industry Context

The acquisition reflects a trend of consolidation in the mental health treatment industry, with companies seeking to expand their market presence and service offerings.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards as the specific terms of the deal, such as the exchange ratio and termination fees, are unique to the circumstances of Neuronetics and Greenbrook.
• However, the document does not provide enough information to make a detailed comparison to industry standards.

Stakeholder Impact

• Shareholders of Greenbrook will receive Neuronetics stock, impacting their investment portfolio.
• Employees of both companies may experience changes in their roles and responsibilities.
• Customers of both companies could see changes in service offerings and availability.
• Suppliers and creditors may be affected by the combined company's financial performance and strategies.

Next Steps

• Obtaining required approvals from Neuronetics stockholders and Greenbrook shareholders.
• Obtaining interim and final orders from the Ontario Superior Court of Justice.
• Ensuring the issuance of Consideration Shares is exempt from registration requirements.
• Maintaining Neuronetics shares listing on the NASDAQ.
• Converting Greenbrook's outstanding debt into Greenbrook Shares.
• Completing the Arrangement on or before the Outside Date (December 10, 2024).

Key Dates

Keywords

Neuronetics, Greenbrook, acquisition, arrangement agreement, merger, stock, shareholders, Madryn, voting agreement, registration rights